Drug combinations and uses in treating a coughing condition

Patent metadata

Field	Value
Publication number	US-10016437-B2
Application number	US-201414287017-A
Country	US
Kind code	B2
Filing date	May 24, 2014
Priority date	Jun 16, 2009
Publication date	Jul 10, 2018
Grant date	Jul 10, 2018

Abstract

The present specification discloses compositions comprising a plurality of therapeutic compound having antitussive activity and methods and uses for treating a coughing condition with such compositions.

First claim

The invention claimed is:

1. An oral pharmaceutical composition comprising 0.5 mg/mL to 10 mg/mL of Theobromine, 0.25 mg/mL to 7.5 mg/mL of Diphenhydramine, and 0.1 mg/mL to 5 mg/mL of Phenylephrine, wherein the pharmaceutical composition does not include a non-opiate antitussive agent and wherein the therapeutically-effective amount of the theobromine is at least 60 mg/day and at most 150 mg/day.

2. The oral pharmaceutical composition according to claim 1 , wherein the oral pharmaceutical composition comprises 0.5 mg/mL to 6 mg/mL of Theobromine, 0.5 mg/mL to 5 mg/mL of Diphenhydramine, and 0.1 mg/mL to 2 mg/mL of Phenylephrine.

3. The oral pharmaceutical composition according to claim 2 , wherein the oral pharmaceutical composition comprises 1 mg/mL to 3 mg/mL of Theobromine, 1 mg/mL to 3 mg/mL of Diphenhydramine, and 0.1 mg/mL to 1 mg/mL of Phenylephrine.

4. The oral pharmaceutical composition according to claim 3 , wherein the oral pharmaceutical composition comprises 2 mg/mL of Theobromine, 1.25 mg/mL of Diphenhydramine, and 0.5 mg/mL of Phenylephrine.

5. A method of treating cough due to a cold, the method comprising the step of administering a therapeutically-effective amount of the oral pharmaceutical composition of claim 1 .

6. The method according to claim 5 , wherein the oral pharmaceutical composition comprises 0.5 mg/mL to 6 mg/mL of Theobromine, 0.5 mg/mL to 5 mg/mL of Diphenhydramine, and 0.1 mg/mL to 2 mg/mL of Phenylephrine.

7. The method according to claim 6 , wherein the oral pharmaceutical composition comprises 1 mg/mL to 3 mg/mL of, 1 mg/mL to 3 mg/mL of Diphenhydramine, and 0.1 mg/mL to 1 mg/mL of Phenylephrine.

8. The method according to claim 7 , wherein the oral pharmaceutical composition comprises 2 mg/mL of Theobromine, 1.25 mg/mL of Diphenhydramine, and 0.5 mg/mL of Phenylephrine.

9. The method according to claim 5 , wherein the therapeutically-effective amount of the oral pharmaceutical composition comprises between 60 mg/day and 150 mg/day of Theobromine, 20 mg/day and 100 mg/day of Diphenhydramine, and 5 mg/day and 50 mg/day of Phenylephrine.

10. The method according to claim 9 , wherein the therapeutically-effective amount of the oral pharmaceutical composition comprises between 60 mg/day and 120 mg/day of Theobromine, 37.5 mg/day and 75 mg/day of Diphenhydramine, and 15 mg/day and 30 mg/day of Phenylephrine.

Assignees

• Infirst Healthcare Ltd

Inventors

• Brew John
• Bannister Robin Mark

Classifications

• A61K31/522 Primary

  having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir · CPC title

• A61K31/137

  Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone} · CPC title

• A61K31/138

  Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377) · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K2300/00

  Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title